Cambium Bio Ltd CMB

ASX · Australia · Health Technology

AUD 0.5500+0.03 (+5.77%)

Market open· Oct 2, 2026, 1:29 AM UTC· AUD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

Cambium Bio Ltd CMB

ASX · Australia · Health Technology

AUD 0.5500+0.03 (+5.77%)

Market open· Oct 2, 2026, 1:29 AM UTC· AUD · Data may be delayed

Prices may be delayed and are for informational purposes only - not investment advice.

+34.15% · 6MFull-screen chart

Open AUD 0.5200High AUD 0.5500Low AUD 0.5200Close AUD 0.5500Volume 1.00K

Oct 2, 2026

Charts by TradingView Lightweight Charts

Key statistics

Previous close: AUD 0.5200
Day range: AUD 0.5200 – AUD 0.5500
52-week range: AUD 0.3400 – AUD 0.6000
Volume: 1.00K
Market cap: AUD 14.72M
Next earnings date: 2027-03-04
Avg. volume (1Y): 4.68K

Performance

1 week

-5.45%

1 month

+33.33%

3 months

+19.54%

6 months

+26.83%

Year to date

+11.83%

1 year

0.00%

Total return, dividends included.

Company profile

Sector: Health Technology
Industry: Biotechnology
Country: Australia
Exchange: ASX
Shares outstanding: 29.43M
ISIN: AU0000327769
Beta: -0.32

Technical view

Above averages

Where the price sits against its 50- and 200-day moving averages.

Valuation & analysis

Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.

News

Yahoo FinanceSep 16, 2026

Cambium Bio Secures A$10.85 Million to Initiate Pivotal Phase 3 Trial of Elate Ocular®, a Potential First-in-Class Biologic for Dry Eye Disease

Strategic shareholders commit A$7.1 million at a premium to market, the Company’s fourth consecutive equity raise priced at a premium, alongside A$3.75 million of non-dilutive R&D Tax Incentive pre-financingSYDNEY, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Cambium Bio Limited (ASX: CMB) (“Cambium Bio” or the “Company”), a clinical-stage regenerative medicine company developing biologic therapies for ophthalmology, today announced that it has secured an A$10.85 million funding package to initiate its pi

Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.